Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer's disease

Neurobiology of Disease

Volumn 33, Issue 3, 2009, Pages 467-472

  Kankaanpää, Jari ^a,b   Turunen, S Pauliina ^a,b   Moilanen, Virpi ^a   Hörkkö, Sohvi ^a,b   Remes, Anne M ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; Antibody; Cerebrospinal fluid; Dementia; Oxidized LDL

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANTIGEN BINDING; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; AGED; ALBUMINS; ALZHEIMER DISEASE; AUTOANTIBODIES; CEREBROSPINAL FLUID; DEMENTIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEUKOCYTES; LIPOPROTEINS, LDL; LUMINESCENCE; MALE; MIDDLE AGED;

EID: 60849138781     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.12.001     Document Type: Article

References (42)

1. Balin B.J., Broadwell R.D., Salcman M., and el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J. Comp. Neurol. 251 (1986) 260-280
2. Banks W.A., Terrell B., Farr S.A., Robinson S.M., Nonaka N., and Morley J.E. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23 (2002) 2223-2226
3. Bassett C.N., Neely M.D., Sidell K.R., Markesbery W.R., Swift L.L., and Montine T.J. Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids 34 (1999) 1273-1280
4. Biere A.L., Ostaszewski B., Stimson E.R., Hyman B.T., Maggio J.E., and Selkoe D.J. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem 271 (1996) 32916-32922
5. Binder C.J., Hörkkö S., Dewan A., Chang M., Kieu E.P., Goodyear C.S., Shaw P.X., Palinski W., Witztum J.L., and Silverman G.J. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9 (2003) 736-743
6. Binder C.J., Shaw P.X., Chang M., Boullier A., Hartvigsen K., Hörkkö S., Miller Y.I., Woelkers D.A., Corr M., and Witztum J.L. The role of natural antibodies in atherogenesis. J. Lipid Res. 46 (2005) 1353-1363
7. Bonda D.J., Webber K.M., Siedlak S.L., Perry G., Friedland R.B., and Smith M.A. The pathology of Alzheimer disease elicits an in vivo immunological response. Am. J. Immunol. 3 (2007) 10-14
8. Borghini I., Barja F., Pometta D., and James R.W. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim. Biophys. Acta 1255 (1995) 192-200
9. Bowman G.L., Kaye J.A., Moore M., Waichunas D., Carlson N.E., and Quinn J.F. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68 (2007) 1809-1814
10. Braak H., and Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82 (1991) 239-259
11. Butterfield D.A., and Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32 (2002) 1050-1060
12. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
13. Da R., Kao G., Guo W., Olek M., Gupta S., Zhang Y., Van Den Noort S., and Qin Y. Polyclonal B-cell expansion in the cerebrospinal fluid of patients with pseudotumor cerebri. J. Clin. Immunol. 24 (2004) 674-682
14. Deane R., Sagare A., Hamm K., Parisi M., LaRue B., Guo H., Wu Z., Holtzman D.M., and Zlokovic B.V. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci. 25 (2005) 11495-11503
15. Freigang S., Hörkkö S., Miller E., Witztum J.L., and Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1972-1982
16. Freund J. Accumulation of antibodies in the central nervous system. J. Exper. Med. 51 (1930) 889-902
17. Friedman P., Horkko S., Steinberg D., Witztum J.L., and Dennis E.A. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of schiff base formation and aldol condensation. J. Biol. Chem. 277 (2002) 7010-7020
18. Hamel E., Nicolakakis N., Aboulkassim T., Ongali B., and Tong X. Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp. Physiol. 93 (2008) 116-120
19. Henkel A.W., Dittrich P.S., Groemer T.W., Lemke E.A., Klingauf J., Klafki H.W., Lewczuk P., Esselmann H., Schwille P., Kornhuber J., and Wiltfang J. Immune complexes of auto-antibodies against A beta 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. Mol. Psychiatry 12 (2007) 601-610
20. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development-clinical and animal studies. Clin. Chim. Acta 348 (2004) 1-8
21. Hörkkö S., Binder C.J., Shaw P.X., Chang M.K., Silverman G., Palinski W., and Witztum J.L. Immunological responses to oxidized LDL. Free Radic. Biol. Med. 28 (2000) 1771-1779
22. Kabat E.A., Moore D.H., and Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J. Clin. Invest. 21 (1942) 571-577
23. Karvonen J., Päivänsalo M., Kesäniemi Y.A., and Hörkkö S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108 (2003) 2107-2112
24. Kivipelto M., Helkala E.L., Laakso M.P., Hänninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., and Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322 (2001) 1447-1451
25. Koudinov A.R., Koudinova N.V., Kumar A., Beavis R.C., and Ghiso J. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem. Biophys. Res. Commun. 223 (1996) 592-597
26. Liu Q., Smith M.A., Avilá J., DeBernardis J., Kansal M., Takeda A., Zhu X., Nunomura A., Honda K., Moreira P.I., Oliveira C.R., Santos M.S., Shimohama S., Aliev G., de la Torre J., Ghanbari H.A., Siedlak S.L., Harris P.L.R., Sayre L.M., and Perry G. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic. Biol. Med. 38 (2005) 746-754
27. McIntyre J.A., Hamilton R.L., and DeKosky S.T. Redox-reactive autoantibodies in cerebrospinal fluids. Ann. N.Y. Acad. Sci. 1109 (2007) 296-302
28. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34 (1984) 939-944
29. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., and Benson D. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51 (1998) 1546-1554
30. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., and Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14 (1994) 605-616
31. Pitas R.E., Boyles J.K., Lee S.H., Hui D., and Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262 (1987) 14352-14360
32. Roheim P.S., Carey M., Forte T., and Vega G.L. Apolipoproteins in human cerebrospinal fluid. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 4646-4649
33. Salonen J.T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssönen K., Palinski W., and Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
34. Sayre L.M., Zelasko D.A., Harris P.L., Perry G., Salomon R.G., and Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68 (1997) 2092-2097
35. Schippling S., Kontush A., Arlt S., Buhmann C., Stürenburg H.J., Mann U., Müller-Thomsen T., and Beisiegel U. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic. Biol. Med. 28 (2000) 351-360
36. Shaw P.X., Hörkkö S., Chang M.K., Curtiss L.K., Palinski W., Silverman G.J., and Witztum J.L. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105 (2000) 1731-1740
37. Shobab L.A., Hsiung G.R., and Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 4 (2005) 841-852
38. Tarkowski E., Andreasen N., Tarkowski A., and Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 74 (2003) 1200-1205
39. Terryberry J.W., Thor G., and Peter J.B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 19 (1998) 205-216
40. Tsimikas S., Brilakis E.S., Lennon R.J., Miller E.R., Witztum J.L., McConnell J.P., Kornman K.S., and Berger P.B. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J. Lipid Res. 48 (2007) 425-433
41. Verbeek M.M., de Waal R.M., Schipper J.J., and Van Nostrand W.E. Rapid degeneration of cultured human brain pericytes by amyloid beta protein. J. Neurochem. 68 (1997) 1135-1141
42. Wardlaw J.M., Sandercock P.A.G., Dennis M.S., and Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?. Stroke 34 (2003) 806-812